Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial

By sjmartinez • June 4, 2024

Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. J Crohns Colitis. 2024 Jun 3;18(6):885-894. doi: 10.1093/ecco-jcc/jjae007. PMID: 38245818; PMCID: PMC11147797.

Tags: Cedars Sinai DoM, Digestive Diseases, endoscopic improvement–histologic remission, Etrasimod, mucosal healing, Publications, S1P receptor modulator, ulcerative colitis

Vessel-density distribution mapping on portal venous CT and deep learning for 2-year overall survival risk stratification after transarterial chemoembolization in hepatocellular carcinoma

Wang C, He Y, Wang Y, Deng Z, Wang L, Li D. Vessel-density distribution mapping on portal venous CT and deep learning for 2-year overall[...]

AI-Derived LA Volume Index, LA/RA and LA/LV Volume Ratios From Coronary Artery Calcium Scans Predict Long-Term Atrial Fibrillation and Stroke

Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Mozafarybazargany M, Hashemi A, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Branch[...]

Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum

Hemeryck J, De Moor N, Ezzat D, Khan RR, Vandergrift N, Levine LD, Rouse C, Theilen LH, Bairey Merz CN, Yee LM, Chung J, Bello[...]